EXEL vs JAZZ
Exelixis, Inc. and Jazz Pharmaceuticals plc, both Healthcare
Jazz Pharmaceuticals plc is the larger company at $14B against $13B. On trailing earnings JAZZ is the cheaper of the two at a P/E of 14.9 against 18.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year JAZZ returned +70% against +49% for EXEL. The RyuScore puts EXEL ahead, 80 against 48 out of 100.
| Figure | EXEL | JAZZ |
|---|---|---|
| Last close | $59.86 | $218 |
| Market cap | $13B | $14B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.8 | 14.9 |
| 1-year return | +49% | +70% |
| 5-year return | +197% | +62% |
| RyuScoresector-relative, 1–10 | 80/100 | 48/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Exelixis, Inc.
Revenue of $629M in Q2 2026, net income $212M. Its largest reported line is Product Gross, 87% of the disclosed total.
Jazz Pharmaceuticals plc
Revenue of $1.2B in Q2 2026, net income $193M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.